Cancer Biomarker Market Size, Share & Trends Analysis Report By Type (Breast, Prostate, Colorectal, Cervical, Liver, Lung Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, And Segment Forecasts, 2018 - 2025

Industry Insights

The global cancer biomarker market size was valued at USD 10.3 billion in the year 2016 and is estimated to reach a value of USD 33.7 billion by 2025, growing with CAGR of 14.3 %. Growing prevalence of malignancies coupled with increasing focus on development of targeted therapies is a major factor affirming the positive growth of this market.

Cancer is reported to be the second leading cause of mortality in the U.S. after cardiovascular disorders. Prevalence of breast, prostate, and lung malignancies has increased at a very steep rate with an estimated number of over 1,600 people being affected in the U.S. every year. In 2017, around 200,000 cases of breast cancer have been reported in the U.S.

U.S. cancer biomarkers market, by application, 2014 - 2025 (USD Billion)

Increasing awareness amongst patients and healthcare professionals about the importance of early diagnosis of malignancies and rising demand for personalized medicine is anticipated to provide this cancer biomarker market with high growth opportunities in the coming decade. Diagnostic biomarkers for early diagnosis enable doctors on deciding better treatment alternatives leading to successful recovery in lesser time.

In addition, increasing regulatory approval of novel drugs and diagnostics pertaining to cancer biomarkers is estimated to increase the adoption rate. For instance, in 2016, Epigenomics AG, a company involved in the development of a novel epigenetic biomarker test announced that its Epi proColon was included by the Chinese government for colorectal cancer (CRC) screening.

Type Insights

Based on type, the market is categorized into breast, prostate, colorectal, cervical, liver, and lung. Breast cancer was the largest segment in 2016. Breast, lung, and prostate cancer cumulatively held the revenue share of over 40% in 2016. Increasing awareness about early testing and growing base of target population are the key factors contributing toward dominance

On the other hand, lung cancer is expected to witness the fastest growth over the forecast period. Growing number of diagnostic tests targeting EGFR and BRAF mutations, which act as an essential biomarker for diagnosis of non-small cell lung cancer are anticipated to accentuate the segment growth.

Biomolecule Insights

Based on the biomolecule, the market is further segmented into genetic, epigenetic, metabolic, and proteomic biomarkers. Genetic biomarkers owing to their extensive usage, high-reliability rate, and easier analysis held a significant market share. Over 85% of malignancies are reported to be detected with the help of genetic and proteomic biomarkers.

Epigenetics has gained high acceptance in the field of cancer diagnostics. High amount of research is being undertaken by many players for the analysis of key epigenetic modification related to cancer for further development of biomarkers targeting drugs. Increasing collaboration between and pharmaceutical companies for the development of novel drugs targeting epigenetic biomarkers is estimated to boost the growth of this segment.

Global cancer biomarkers market, by biomolecule, 2016 (%)

Application Insights

Cancer biomolecules find application in various fields such as drug discovery and development, diagnostics, and personalized medicine. Diagnostics were the key revenue-generating application of the market pertaining to factors such as increasing development of biomarker-based oncology tests with high specificity and sensitivity.

Personalized medicine owing to its increasing demand and rising awareness amongst healthcare professionals is anticipated to witness flourishing growth rate. Moreover, growing approval for companion diagnostic tests for cancer drugs is expected to affirm market growth.

Regional Insights

North America dominated the regional segment followed closely by Europe. High adoption of innovative technology, presence of key pharmaceutical companies, established R&D infrastructure pertaining to the development of novel diagnostic products and increased demand for specific & early diagnostics are the major factors for the aforementioned dominance.

However, the Asia Pacific region owing to increasing prevalence of cancer, beneficial environment for clinical trials, and increasing government funding for supporting drug development programs is anticipated to witness lucrative CAGR over the forecast period. Moreover, growing focus of pharmaceutical companies over this region coupled with rising awareness for biomarker-based diagnosis is one of the high impact-rendering drivers for growth.

Cancer Biomarker Market Share Insights

Abbott Laboratories; F.Hoffmann-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific Inc.; Affymetrix Inc.; Illumina, Inc.; Agilent Technologies; Merck & Co. Inc.; Hologic, Inc.; Sino Biological Inc.; and Becton, Dickinson and Company are some of the key players of the market.

New product development, collaborative agreements with research institutes for the development of novel biomarkers and mergers & acquisitions of small players are the key strategies implemented by these players to attain a stable market position.

Report Scope

Segments Covered in the report

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global cancer biomarker market on the basis of type, biomolecules, type, application, and region:

• Type Outlook (Revenue, USD Billion; 2014 - 2025)

  • Breast cancer

  • Prostate cancer

  • Colorectal cancer

  • Cervical cancer

  • Liver cancer

  • Lung cancer

  • Others

• Biomolecule Outlook (Revenue, USD Billion; 2014 - 2025)

  • Genetic Biomarkers

  • Epigenetic Biomarkers

  • Metabolic Biomarkers

  • Proteomic Biomarkers

  • Others

• Application Outlook (Revenue, USD Billion; 2014 - 2025)

  • Drug discovery and Development

  • Diagnostics

  • Personalized medicine

  • Others

• Regional Outlook (Revenue, USD Billion; 2014 - 2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • China

    • Japan

  • Latin America

    • Mexico

    • Brazil

  • MEA

    • South Africa